NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) insider Martha Morrell sold 3,200 shares of the firm's stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $15.01, for a total transaction of $48,032.00. Following the transaction, the insider now directly owns 87,062 shares of the company's stock, valued at $1,306,800.62. This represents a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
NeuroPace Stock Performance
NPCE traded down $0.11 during trading hours on Tuesday, reaching $14.13. The company's stock had a trading volume of 99,653 shares, compared to its average volume of 141,674. The company's 50-day moving average is $11.44 and its 200-day moving average is $8.69. NeuroPace, Inc. has a 52 week low of $5.45 and a 52 week high of $18.15. The firm has a market cap of $421.78 million, a PE ratio of -14.13 and a beta of 2.02. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59.
NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $21.06 million during the quarter, compared to analysts' expectations of $19.33 million. During the same quarter last year, the company posted ($0.28) EPS. On average, equities analysts forecast that NeuroPace, Inc. will post -1 EPS for the current year.
Institutional Investors Weigh In On NeuroPace
A number of institutional investors have recently made changes to their positions in NPCE. KCK LTD. acquired a new stake in NeuroPace during the 4th quarter worth approximately $58,981,000. Millennium Management LLC increased its position in NeuroPace by 13.3% during the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company's stock worth $5,186,000 after buying an additional 80,324 shares during the period. Geode Capital Management LLC lifted its holdings in shares of NeuroPace by 8.7% during the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company's stock worth $2,211,000 after buying an additional 25,330 shares in the last quarter. State Street Corp boosted its position in shares of NeuroPace by 9.1% in the third quarter. State Street Corp now owns 155,490 shares of the company's stock valued at $1,084,000 after acquiring an additional 12,912 shares during the period. Finally, XTX Topco Ltd grew its stake in shares of NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company's stock valued at $182,000 after acquiring an additional 8,643 shares in the last quarter. Institutional investors own 78.83% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts recently commented on NPCE shares. JPMorgan Chase & Co. increased their target price on shares of NeuroPace from $9.00 to $14.00 and gave the stock an "overweight" rating in a report on Tuesday, December 17th. UBS Group initiated coverage on NeuroPace in a report on Tuesday, January 21st. They issued a "buy" rating and a $17.00 price objective for the company. Finally, Wells Fargo & Company lowered their target price on shares of NeuroPace from $15.00 to $13.00 and set an "overweight" rating on the stock in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, NeuroPace has a consensus rating of "Moderate Buy" and a consensus target price of $15.33.
View Our Latest Analysis on NeuroPace
About NeuroPace
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
